GENE

Genetic Technologies Limited (GTG) is an Australia-based molecular diagnostics company. The Company offers predictive genetic testing and risk assessment tools. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its GeneType and EasyDNA brands. The Company operates through three segments: EasyDNA, AffinityDNA, and geneType / Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. The geneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. GeneType also offers integrated risk testing for a range of serious conditions. EasyDNA and AffinityDNA offer deoxyribonucleic acid (DNA) testing services.